A Commitment to Impact
Pi Health is dedicated to making clinical research inclusive, efficient, and impactful. Our mission is to eliminate barriers, accelerate breakthrough therapies, and ensure diverse patient populations benefit from innovative medical advances.
Leadership
Bobby Reddy, MD
Chief Executive Officer
Dr. Bobby Reddy, MD is the Chief Executive Officer of Pi Health. At Pi Health, he leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world.
Previously, he served in leadership positions at BeOne Medicines and AstraZeneca. At BeOne, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Previously, he served in leadership positions at BeOne Medicines and AstraZeneca. At BeOne, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Kevin Stenerson
Chief Technology Officer
Kevin Stenerson is the Chief Technology Officer at Pi Health, where he leads the engineering and development of the company's AI-driven clinical research platform. With over 15 years of experience building and scaling technology organizations, he brings a proven track record of transforming engineering teams and delivering systems that create meaningful impact in healthcare and enterprise software.
Most recently, Kevin served as Senior Director and Principal Engineer at AuditBoard, where he played a pivotal role in the company's dramatic growth trajectory. During his tenure, he scaled the engineering organization from 25 to over 100 engineers, architected high-performance systems that supported platform revenue growth from $17M to over $170M, and established engineering management processes that enabled sustainable scale. His technical leadership and organizational development contributed significantly to AuditBoard's successful $3 billion acquisition by HG in July 2024.
Kevin's expertise in healthcare technology reflects years of developing solutions for patient care. At Reflexion Health, he developed innovative telemedicine technology in collaboration with Mayo Clinic and other leading healthcare institutions. His work on physical therapy solutions for post-surgical knee and hip replacement patients enabled earlier hospital discharge and improved therapy adherence. The technology used computer vision AI to guide patients safely through home exercises while automatically flagging movement deficits to clinicians, making specialized care accessible to patients in distant and rural communities who would otherwise struggle with post-operative care access.
At Flint Clinical, Kevin served as Head of Engineering, where he built software solutions that streamlined clinical trial budgeting for biotechnology companies and clinics specializing in dermatology.
Beyond healthcare, as Co-Founder of Wyyerd Fiber, Kevin established a telecommunications company focused on bringing fiber-to-the-home services to markets dominated by legacy providers. He led the company through its initial capital raise, developed greenfield markets, and oversaw the acquisition and expansion of fiber infrastructure in Phoenix, Arizona, before successfully exiting during a subsequent funding round.
Throughout his career, Kevin has driven successful outcomes across diverse industries including healthcare technology, enterprise SaaS, telecommunications, regulatory compliance systems, and payment platforms. His experience spans founding startups, scaling engineering teams at billion-dollar companies, and building technology that creates lasting impact.
Kevin holds a B.S. from the University of Colorado Boulder. He believes in building systems that scale, teams that innovate, and technology that serves a larger purpose - whether improving patient outcomes, enabling economic growth, or opening new possibilities for innovation.
Most recently, Kevin served as Senior Director and Principal Engineer at AuditBoard, where he played a pivotal role in the company's dramatic growth trajectory. During his tenure, he scaled the engineering organization from 25 to over 100 engineers, architected high-performance systems that supported platform revenue growth from $17M to over $170M, and established engineering management processes that enabled sustainable scale. His technical leadership and organizational development contributed significantly to AuditBoard's successful $3 billion acquisition by HG in July 2024.
Kevin's expertise in healthcare technology reflects years of developing solutions for patient care. At Reflexion Health, he developed innovative telemedicine technology in collaboration with Mayo Clinic and other leading healthcare institutions. His work on physical therapy solutions for post-surgical knee and hip replacement patients enabled earlier hospital discharge and improved therapy adherence. The technology used computer vision AI to guide patients safely through home exercises while automatically flagging movement deficits to clinicians, making specialized care accessible to patients in distant and rural communities who would otherwise struggle with post-operative care access.
At Flint Clinical, Kevin served as Head of Engineering, where he built software solutions that streamlined clinical trial budgeting for biotechnology companies and clinics specializing in dermatology.
Beyond healthcare, as Co-Founder of Wyyerd Fiber, Kevin established a telecommunications company focused on bringing fiber-to-the-home services to markets dominated by legacy providers. He led the company through its initial capital raise, developed greenfield markets, and oversaw the acquisition and expansion of fiber infrastructure in Phoenix, Arizona, before successfully exiting during a subsequent funding round.
Throughout his career, Kevin has driven successful outcomes across diverse industries including healthcare technology, enterprise SaaS, telecommunications, regulatory compliance systems, and payment platforms. His experience spans founding startups, scaling engineering teams at billion-dollar companies, and building technology that creates lasting impact.
Kevin holds a B.S. from the University of Colorado Boulder. He believes in building systems that scale, teams that innovate, and technology that serves a larger purpose - whether improving patient outcomes, enabling economic growth, or opening new possibilities for innovation.
Paulo Tioseco
Head of Engineering
Paulo Tioseco is the Head of Engineering at Pi Health, where he leads product development and drives the growth of a high-performing engineering organization. With over a decade of experience in software development and technical leadership, Paulo brings deep expertise in scaling teams and delivering complex technology products.
Before joining Pi Health, Paulo led engineering teams at Amazon, where he played a pivotal role in launching two major initiatives: AWS Outposts and Project Kuiper. At AWS Outposts, his team built services to automate the provisioning of edge computing hardware, scaling from zero to over 100 deployments at customer sites in the first year of general availability. At Project Kuiper, he led the engineering organization that built, from the ground up, the command-and-control systems enabling communication between Amazon’s low Earth orbit satellites and ground stations, a historic first for the company.
Earlier in his career, Paulo held technical and leadership roles at high-growth technology companies such as Space Exploration Technologies (SpaceX), EdgeCast Networks (acquired by Verizon), and Apriso (acquired by Dassault Systèmes). He also co-founded Tourjive, a data analytics startup for the live music industry. Today, he continues to support innovation as an angel investor, with a focus on hardware and AI startups.
While in university, before the advent of modern cloud computing, Paulo conducted research and development on a distributed system to query and retrieve medical images using the DICOM standard (Digital Imaging and Communications in Medicine) from remote hospitals via a central location. With this background and a proven track record of delivering cutting-edge products at scale, Paulo is well-positioned to lead the engineering efforts that enable Pi Health to deliver on its mission to democratize and accelerate clinical trials, and ultimately, to save lives.
Before joining Pi Health, Paulo led engineering teams at Amazon, where he played a pivotal role in launching two major initiatives: AWS Outposts and Project Kuiper. At AWS Outposts, his team built services to automate the provisioning of edge computing hardware, scaling from zero to over 100 deployments at customer sites in the first year of general availability. At Project Kuiper, he led the engineering organization that built, from the ground up, the command-and-control systems enabling communication between Amazon’s low Earth orbit satellites and ground stations, a historic first for the company.
Earlier in his career, Paulo held technical and leadership roles at high-growth technology companies such as Space Exploration Technologies (SpaceX), EdgeCast Networks (acquired by Verizon), and Apriso (acquired by Dassault Systèmes). He also co-founded Tourjive, a data analytics startup for the live music industry. Today, he continues to support innovation as an angel investor, with a focus on hardware and AI startups.
While in university, before the advent of modern cloud computing, Paulo conducted research and development on a distributed system to query and retrieve medical images using the DICOM standard (Digital Imaging and Communications in Medicine) from remote hospitals via a central location. With this background and a proven track record of delivering cutting-edge products at scale, Paulo is well-positioned to lead the engineering efforts that enable Pi Health to deliver on its mission to democratize and accelerate clinical trials, and ultimately, to save lives.
Ro Wickramasinghe, PhD
Chief Business Officer
Dr Ro Wickramasinghe is the Chief Business Officer at Pi Health, where he leads Strategic Partnerships with Pharmaceutical and Biotech sponsors, as well as with Clinical Trial Sites. He also oversees Pi Health’s Business Operations across Australia and Europe.
Ro is a seasoned industry leader and brings over 15 years of experience in Business Development roles across the Pharma, Biotech, and HealthTech sectors. His career includes multiple leadership roles, with a consistent track record of executing transformative deals that have helped shape Standards of Care in Oncology.
At BeOne, where Pi Health was originally incubated, Ro led Commercial and Business Development within the Applied Innovation Group. Prior to that, as Vice President and Head of Business Development at Ellipses Pharma, he built out key functions - including Search & Evaluation, Transactions, Analytics, and Clinical Strategy - and successfully in-licensed five oncology assets within two years.
Earlier in his career at AstraZeneca, Ro was a core member of the Oncology Business Development team. He was a key contributor to many Business Development transactions ranging from in-licensing to divestments and also clinical collaborations to support AstraZeneca’s key franchises. Highlights include leading the $300 million divestment of rare disease therapy Caprelsa to Sanofi/Genzyme, and playing a pivotal role in initiating the landmark $6.9 billion collaboration with Daiichi Sankyo for the HER2-ADC trastuzumab deruxtecan (now Enhertu), an ADC which has since changed Standard of Care in numerous indications. He also led multiple clinical collaborations to support the lifecycle management of PD-L1 inhibitor Imfinzi, including with TROP2-ADC sacituzumab govitecan (now Trodelvy) from Immunomedics (since sold to Gilead for $21bn), and AstraZeneca’s oral SERD AZD9833 Camizestrant (now with a positive Phase 3) and injectable SERD Faslodex in breast cancer.
Ro holds a PhD in Oncology from Trinity College, University of Cambridge, where he was a Gates Scholar, and an MBA from the Cambridge Judge Business School. He also earned a Bachelor of Science (Honours) and a Bachelor of Biomedical Science from the University of Melbourne, Australia.
Ro is a seasoned industry leader and brings over 15 years of experience in Business Development roles across the Pharma, Biotech, and HealthTech sectors. His career includes multiple leadership roles, with a consistent track record of executing transformative deals that have helped shape Standards of Care in Oncology.
At BeOne, where Pi Health was originally incubated, Ro led Commercial and Business Development within the Applied Innovation Group. Prior to that, as Vice President and Head of Business Development at Ellipses Pharma, he built out key functions - including Search & Evaluation, Transactions, Analytics, and Clinical Strategy - and successfully in-licensed five oncology assets within two years.
Earlier in his career at AstraZeneca, Ro was a core member of the Oncology Business Development team. He was a key contributor to many Business Development transactions ranging from in-licensing to divestments and also clinical collaborations to support AstraZeneca’s key franchises. Highlights include leading the $300 million divestment of rare disease therapy Caprelsa to Sanofi/Genzyme, and playing a pivotal role in initiating the landmark $6.9 billion collaboration with Daiichi Sankyo for the HER2-ADC trastuzumab deruxtecan (now Enhertu), an ADC which has since changed Standard of Care in numerous indications. He also led multiple clinical collaborations to support the lifecycle management of PD-L1 inhibitor Imfinzi, including with TROP2-ADC sacituzumab govitecan (now Trodelvy) from Immunomedics (since sold to Gilead for $21bn), and AstraZeneca’s oral SERD AZD9833 Camizestrant (now with a positive Phase 3) and injectable SERD Faslodex in breast cancer.
Ro holds a PhD in Oncology from Trinity College, University of Cambridge, where he was a Gates Scholar, and an MBA from the Cambridge Judge Business School. He also earned a Bachelor of Science (Honours) and a Bachelor of Biomedical Science from the University of Melbourne, Australia.
Smruthi Panyam
Head of Clinical Data Strategy and Stewardship
Smruthi Panyam is an accomplished life sciences leader with over 21 years of global experience driving clinical data innovation and operational excellence across the pharmaceutical, biotech, and CRO industries. Currently serving as Vice President of Clinical Data Strategy and Stewardship at Pi Health Inc., she plays a pivotal role in shaping clinical technology infrastructure and strategic data operations. Smruthi brings deep expertise in global clinical trial delivery, regulatory compliance, and data lifecycle management, having successfully led and submitted clinical trials across the U.S., Europe, and Asia.
Renowned for her transformational leadership, Smruthi has consistently delivered clinical trials in accelerated timelines to highest quality. Her portfolio includes leading complex merger and acquisition transitions, orchestrating trial rescue operations, and spearheading enterprise-level process improvements that have boosted trial efficiency, safety oversight, and data quality.
Her previous leadership roles at BeOne Medicines and AstraZeneca saw her champion cross-functional collaboration, innovation, streamline operations, and pioneer automation and technology solutions that significantly improved speed, accuracy, and scalability in data review processes. With a background in dentistry and formal training in Lean, Agile, and Scaled Agile methodologies, Smruthi is a rare blend of clinical insight and technical acumen.
Fluent in English, with working knowledge of Japanese, Polish and German, Smruthi is also a seasoned mentor and team builder, committed to fostering collaborative cultures that elevate both people and performance in pursuit of patient-centric, regulatory compliant, data-driven solutions.
Renowned for her transformational leadership, Smruthi has consistently delivered clinical trials in accelerated timelines to highest quality. Her portfolio includes leading complex merger and acquisition transitions, orchestrating trial rescue operations, and spearheading enterprise-level process improvements that have boosted trial efficiency, safety oversight, and data quality.
Her previous leadership roles at BeOne Medicines and AstraZeneca saw her champion cross-functional collaboration, innovation, streamline operations, and pioneer automation and technology solutions that significantly improved speed, accuracy, and scalability in data review processes. With a background in dentistry and formal training in Lean, Agile, and Scaled Agile methodologies, Smruthi is a rare blend of clinical insight and technical acumen.
Fluent in English, with working knowledge of Japanese, Polish and German, Smruthi is also a seasoned mentor and team builder, committed to fostering collaborative cultures that elevate both people and performance in pursuit of patient-centric, regulatory compliant, data-driven solutions.
Mitch Yarchin
Head of Product
Mitch Yarchin is a startup leader and entrepreneur with over 15 years of experience in healthtech and enterprise SaaS. As founding Head of Product at Preveta, he launched data-driven AI solutions adopted by several leading healthcare organizations in the oncology space. Previously, he led product management at AuditBoard, supporting growth to over $150 million in ARR and successful acquisition. Mitch is known for building high-performing teams, delivering complex data integrations, and driving innovative products that solve real-world problems.
Steve Reyes, PhD
Head of Clinical Operations & Development
Steve Reyes leads the Clinical Operations & Development function enhancing clinical trial efficiency and leveraging technology to drive innovative solutions. He obtained his PhD in Cancer Biology from MD Anderson, researching novel mechanisms of glioblastoma. For over a decade he has optimized operational strategies, integrated transformative technologies into the clinical trial process, and contributed to advancements in clinical trial execution.
Prior to joining Pi Health, Steve oversaw numerous clinical trials and led assets from FIH to approval during his time with LabCorp’s clinical trial division (now Fortrea), Syneos Health, as well as Intellia Therapeutics. Steve is a dedicated and versatile clinical development leader with extensive experience developing therapeutic platforms including gene editing, lipid nanoparticles, small molecules, antibodies, antibody drug conjugates (ADC), adeno-associated viruses (AAV), and cell therapies (autologous and allogeneic). He has built delivery teams that range from biotechs to clinical research organizations (CROs). Known for driving operational excellence from organizational frameworks to individual study execution, Steve has expertise developing assets spanning oncology, rare diseases, gastrointestinal, infectious disease, and cardiovascular indications.
Prior to joining Pi Health, Steve oversaw numerous clinical trials and led assets from FIH to approval during his time with LabCorp’s clinical trial division (now Fortrea), Syneos Health, as well as Intellia Therapeutics. Steve is a dedicated and versatile clinical development leader with extensive experience developing therapeutic platforms including gene editing, lipid nanoparticles, small molecules, antibodies, antibody drug conjugates (ADC), adeno-associated viruses (AAV), and cell therapies (autologous and allogeneic). He has built delivery teams that range from biotechs to clinical research organizations (CROs). Known for driving operational excellence from organizational frameworks to individual study execution, Steve has expertise developing assets spanning oncology, rare diseases, gastrointestinal, infectious disease, and cardiovascular indications.
Fabiana Saad, FNP-C
Head of Commercial Operations & General Manager of LATAM
Fabiana Saad is the Head of Commercial Operations & General Manager of LATAM at Pi Health. She leads client relationships, operational delivery, and customer success to ensure Pi Health's technology platform is seamlessly adopted by sponsors and sites. As General Manager of LATAM, she oversees all aspects of Pi Health's business throughout the region—from strategic direction and partnerships to day-to-day operations—with a special focus on Brazil.
Fabiana began her career as a Family Nurse Practitioner serving underserved populations. As a lead provider, she quickly developed an interest in operations by redesigning practice workflows to address inefficiencies. Her commitment to healthcare innovation led her to health-tech startups, including Firefly Health, where as a founding Nurse Practitioner she provided hybrid clinical care while collaborating with product, design, and engineering teams to build a proprietary health technology platform. Most recently, as Director of Healthcare Solutions in Applied Innovations at BeOne Medicines, she served as a clinical subject matter expert to develop a clinical interface and spearheaded its launch in Brazil's oncology market.
Her leadership philosophy is rooted in the belief that every patient, regardless of location or background, deserves access to the latest medical advances. She has volunteered in Brazil, Haiti, and the Boston area, and is fluent in Portuguese, English, and Spanish.
Fabiana earned her MSN (Family Nurse Practitioner) and BSN from Johns Hopkins University and maintains board certification as a Family Nurse Practitioner with an active license in Massachusetts.
Fabiana began her career as a Family Nurse Practitioner serving underserved populations. As a lead provider, she quickly developed an interest in operations by redesigning practice workflows to address inefficiencies. Her commitment to healthcare innovation led her to health-tech startups, including Firefly Health, where as a founding Nurse Practitioner she provided hybrid clinical care while collaborating with product, design, and engineering teams to build a proprietary health technology platform. Most recently, as Director of Healthcare Solutions in Applied Innovations at BeOne Medicines, she served as a clinical subject matter expert to develop a clinical interface and spearheaded its launch in Brazil's oncology market.
Her leadership philosophy is rooted in the belief that every patient, regardless of location or background, deserves access to the latest medical advances. She has volunteered in Brazil, Haiti, and the Boston area, and is fluent in Portuguese, English, and Spanish.
Fabiana earned her MSN (Family Nurse Practitioner) and BSN from Johns Hopkins University and maintains board certification as a Family Nurse Practitioner with an active license in Massachusetts.
Todd Palmby, PhD
Chief Scientific Officer & Head of Regulatory Affairs
Dr. Todd Palmby is an accomplished leader with over two decades of experience in biopharmaceutical development, regulatory affairs, and precision oncology research. He currently serves as Chief Scientific Officer and Head of Regulatory Affairs at Pi Health, where he leads cross-functional teams and provides strategic scientific and regulatory guidance to advance biopharmaceutical client programs while driving continued growth of Pi Health's services and technology platforms.
Dr. Palmby's distinguished career includes a senior leadership role in North America Regulatory Affairs at BeOne Medicines, where he served as Head of Regulatory Integration. In this role, he guided regulatory and scientific experts in developing innovative approaches to critical regulatory issues including dose optimization, combination strategies, and real-world evidence applications. He supported business development through regulatory review of potential licensing and partnership opportunities and provided strategic regulatory leadership as a member of the Early Development Committee.
Prior to BeOne, Dr. Palmby played a key role in shaping early oncology development strategy for both the Oncology Business Unit and Oncology Research and Development at AstraZeneca. As a member of the Oncology R&D Strategy Leadership Team, he worked closely with cross-functional product development team leaders to create strategies for delivering the oncology early-stage pipeline, conducted market assessments and revenue forecasts to support portfolio investment decisions, and integrated competitor data to drive long-term strategic planning for early-stage projects.
His regulatory expertise was honed during nearly ten years at the U.S. Food and Drug Administration, where he supervised a team of pharmacology/toxicology reviewers in the Division of Hematology Oncology Toxicology. In this role, he provided oversight on reviews for oncology drug applications from pre-IND through post-marketing for small and large molecule products. He was a member of the Pharmacology and Toxicology Coordinating Committee and contributed to the development and revision of multiple FDA and ICH guidance documents. He played active roles in organizing and presenting in key multi-disciplinary workshops on various topics, including oncology dose-finding and cardiovascular toxicity assessment of oncology therapies.
Dr. Palmby earned his Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill and completed his post-doctoral fellowship at the National Institutes of Health. He has authored numerous peer-reviewed publications in leading scientific journals and is recognized for his expertise spanning mechanisms of cancer biology, the integration of multimodal clinical data systems to drive precision oncology, early and late-stage drug development, clinical trial design and strategy, and nonclinical and clinical regulatory strategy. His unique combination of regulatory, scientific, and industry experience positions him as a trusted advisor in navigating the complex landscape of modern biopharmaceutical development.
Dr. Palmby's distinguished career includes a senior leadership role in North America Regulatory Affairs at BeOne Medicines, where he served as Head of Regulatory Integration. In this role, he guided regulatory and scientific experts in developing innovative approaches to critical regulatory issues including dose optimization, combination strategies, and real-world evidence applications. He supported business development through regulatory review of potential licensing and partnership opportunities and provided strategic regulatory leadership as a member of the Early Development Committee.
Prior to BeOne, Dr. Palmby played a key role in shaping early oncology development strategy for both the Oncology Business Unit and Oncology Research and Development at AstraZeneca. As a member of the Oncology R&D Strategy Leadership Team, he worked closely with cross-functional product development team leaders to create strategies for delivering the oncology early-stage pipeline, conducted market assessments and revenue forecasts to support portfolio investment decisions, and integrated competitor data to drive long-term strategic planning for early-stage projects.
His regulatory expertise was honed during nearly ten years at the U.S. Food and Drug Administration, where he supervised a team of pharmacology/toxicology reviewers in the Division of Hematology Oncology Toxicology. In this role, he provided oversight on reviews for oncology drug applications from pre-IND through post-marketing for small and large molecule products. He was a member of the Pharmacology and Toxicology Coordinating Committee and contributed to the development and revision of multiple FDA and ICH guidance documents. He played active roles in organizing and presenting in key multi-disciplinary workshops on various topics, including oncology dose-finding and cardiovascular toxicity assessment of oncology therapies.
Dr. Palmby earned his Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill and completed his post-doctoral fellowship at the National Institutes of Health. He has authored numerous peer-reviewed publications in leading scientific journals and is recognized for his expertise spanning mechanisms of cancer biology, the integration of multimodal clinical data systems to drive precision oncology, early and late-stage drug development, clinical trial design and strategy, and nonclinical and clinical regulatory strategy. His unique combination of regulatory, scientific, and industry experience positions him as a trusted advisor in navigating the complex landscape of modern biopharmaceutical development.
Stacey Gibilisco
Head of Human Resources
Stacey Gibilisco, Head of Human Resources at Pi Health, oversees all aspects of the company’s HR function, including employee relations, talent strategy, benefits, and organizational operations. With more than 20 years of experience across healthcare, pharmaceuticals, and life sciences, Stacey brings deep expertise in full-cycle recruitment, physician relations, and sales leadership. She has a proven track record of designing and executing people-focused initiatives that fuel business growth, strengthen employee engagement, and support a purpose-driven culture.
Before joining Pi Health, Stacey was part of BeOne Medicines' Talent Acquisition team and later served as the Director of External Engagement. She also managed recruitment efforts for top biopharma clients at IQVIA and spent over a decade leading physician engagement at Hackensack Meridian Health. Earlier in her career, she held commercial and recruiting positions at Johnson & Johnson and Pfizer, building a well-rounded foundation in field operations and talent development.
Stacey’s diverse background informs a people-first HR philosophy that supports performance, inclusion, and innovation. She also leads Pi Health’s employee benefit programs, ensuring they evolve with the needs of a growing and engaged workforce. Stacey holds a Bachelor of Science in Public Health Administration from Richard Stockton College of New Jersey and enjoys spending time at the Jersey Shore with her family.
Before joining Pi Health, Stacey was part of BeOne Medicines' Talent Acquisition team and later served as the Director of External Engagement. She also managed recruitment efforts for top biopharma clients at IQVIA and spent over a decade leading physician engagement at Hackensack Meridian Health. Earlier in her career, she held commercial and recruiting positions at Johnson & Johnson and Pfizer, building a well-rounded foundation in field operations and talent development.
Stacey’s diverse background informs a people-first HR philosophy that supports performance, inclusion, and innovation. She also leads Pi Health’s employee benefit programs, ensuring they evolve with the needs of a growing and engaged workforce. Stacey holds a Bachelor of Science in Public Health Administration from Richard Stockton College of New Jersey and enjoys spending time at the Jersey Shore with her family.
Tarun Srivastava
Head of Quality and GxP Compliance
Tarun Srivastava brings over two decades of experience in the Life Sciences industry, with deep expertise in digital transformation, regulatory compliance, and GxP systems. As Vice President, Head of Quality and GxP Compliance at Pi Health, he leads the development of scalable Quality and CSV frameworks that support the company’s mission to modernize clinical trial systems.
Tarun has delivered strategic consulting engagements and led major quality systems programs for top-tier organizations including Millennium Pharmaceuticals/Takeda Oncology, GlaxoSmithKline/Human Genome Sciences, Novartis, Teva, Abbott, and Avara Pharmaceutical Services. At Avara, a global CMO, Tarun led the IT Quality Systems Program across GMP sites in North America and Europe during a complex post-acquisition phase. He implemented key GxP systems—including LabVantage LIMS, Waters Empower CDS, and lab platforms—under strict Transition Services Agreements (TSAs). His work supported integration and compliance efforts involving global leaders such as Merck, Astellas, and UCB.
An entrepreneur at heart, Tarun has founded or scaled consulting ventures including Zenovative Solutions, Nivasoft Inc., and Spectrasoft Technologies, building GxP-focused service offerings and offshore delivery models. He forged strategic partnerships with platforms like Sparta Systems, Dot Compliance, ValGenesis, and Canea, leading multimillion-dollar initiatives and establishing his firms as trusted partners in Honeywell Sparta Systems’ global programs.
Tarun holds an MBA and a Master’s in Management Information Systems and is a certified PMP and ISO Lead Auditor, with additional credentials in CSV, TrackWise, IT Service Management, and Business Analysis.
Tarun has delivered strategic consulting engagements and led major quality systems programs for top-tier organizations including Millennium Pharmaceuticals/Takeda Oncology, GlaxoSmithKline/Human Genome Sciences, Novartis, Teva, Abbott, and Avara Pharmaceutical Services. At Avara, a global CMO, Tarun led the IT Quality Systems Program across GMP sites in North America and Europe during a complex post-acquisition phase. He implemented key GxP systems—including LabVantage LIMS, Waters Empower CDS, and lab platforms—under strict Transition Services Agreements (TSAs). His work supported integration and compliance efforts involving global leaders such as Merck, Astellas, and UCB.
An entrepreneur at heart, Tarun has founded or scaled consulting ventures including Zenovative Solutions, Nivasoft Inc., and Spectrasoft Technologies, building GxP-focused service offerings and offshore delivery models. He forged strategic partnerships with platforms like Sparta Systems, Dot Compliance, ValGenesis, and Canea, leading multimillion-dollar initiatives and establishing his firms as trusted partners in Honeywell Sparta Systems’ global programs.
Tarun holds an MBA and a Master’s in Management Information Systems and is a certified PMP and ISO Lead Auditor, with additional credentials in CSV, TrackWise, IT Service Management, and Business Analysis.
Joel Park
Head of Technology Operations and CISO
Joel Park serves as the Head of Technology Operations and CISO
at Pi Health. Beyond leading the security program, he oversees the company's cloud-native infrastructure and technology operations. His scope encompasses the comprehensive business of technology—ranging from governance and procurement to vendor negotiations and fiscal planning—while maintaining a hands-on engineering focus.
Joel actively contributes to backend API development and DevOps engineering. He also leads the organization's service management strategy, driving the implementation of observability platforms and ITIL frameworks for change and release management. He built the company's technology and security programs from the ground up, achieving zero-exception SOC 2 Type 2 and HIPAA attestation.
Prior to Pi Health, Joel directed medical informatics and digital transformation initiatives at BeOne Medicines. He holds a Master of Science in Data Science from the City University of New York and an MD from Rutgers University.
Joel actively contributes to backend API development and DevOps engineering. He also leads the organization's service management strategy, driving the implementation of observability platforms and ITIL frameworks for change and release management. He built the company's technology and security programs from the ground up, achieving zero-exception SOC 2 Type 2 and HIPAA attestation.
Prior to Pi Health, Joel directed medical informatics and digital transformation initiatives at BeOne Medicines. He holds a Master of Science in Data Science from the City University of New York and an MD from Rutgers University.
Board of Directors
Rohan Ganesh
Board Director Partner, Obvious Ventures
Rohan invests in mission-driven team building companies that transform pharma operations and catalyze biological breakthroughs.
Prior to joining Obvious, he led venture investments in biotech, diagnostics, and healthcare technology companies at Verily Life Sciences, a Google spinout, and at Northpond Ventures, a life-sciences focused venture firm. He started his career in product management roles at CompuGroup Medical, building electronic medical records, and at Verily, productizing neural networks for diagnostic applications.
Rohan studied Biological Sciences at the University of Oxford and earned an MBA from Harvard Business School.
Prior to joining Obvious, he led venture investments in biotech, diagnostics, and healthcare technology companies at Verily Life Sciences, a Google spinout, and at Northpond Ventures, a life-sciences focused venture firm. He started his career in product management roles at CompuGroup Medical, building electronic medical records, and at Verily, productizing neural networks for diagnostic applications.
Rohan studied Biological Sciences at the University of Oxford and earned an MBA from Harvard Business School.
Vishal Vasishth
Board Observer, Co-Founder and Managing Director, Obvious Ventures
Vishal invests in values-driven founders and companies that dramatically improve healthcare outcomes, create more human-centered financial systems, and reimagine consumer services from the ground up.
He leads Obvious’ investments in full-stack healthcare with Virta, Galileo, and Devoted Health; financial technology startups such as Hedvig, One, Corvus, and Openly; and purpose-led consumer services like Good Eggs and Block Renovation.
Before co-founding Obvious, Vishal was the founding partner of Indian-based fund SONG Investment Advisors. He also served as a senior executive at Steve Case’s Revolution, LLC. Prior to his career as an investor, Vishal spent a decade at outdoor gear and apparel retailer Patagonia, in roles ranging from product manager to Chief Strategy Officer. He was selected as a Henry Crown Fellow of the Aspen Institute and a Next Generation Fellow of the American Assembly, both recognizing value-based leadership. Vishal earned a B. Tech degree in India, an MS from North Carolina State University, and an MBA from UCLA’s Anderson School of Management.
He leads Obvious’ investments in full-stack healthcare with Virta, Galileo, and Devoted Health; financial technology startups such as Hedvig, One, Corvus, and Openly; and purpose-led consumer services like Good Eggs and Block Renovation.
Before co-founding Obvious, Vishal was the founding partner of Indian-based fund SONG Investment Advisors. He also served as a senior executive at Steve Case’s Revolution, LLC. Prior to his career as an investor, Vishal spent a decade at outdoor gear and apparel retailer Patagonia, in roles ranging from product manager to Chief Strategy Officer. He was selected as a Henry Crown Fellow of the Aspen Institute and a Next Generation Fellow of the American Assembly, both recognizing value-based leadership. Vishal earned a B. Tech degree in India, an MS from North Carolina State University, and an MBA from UCLA’s Anderson School of Management.
Michael Schoen
Board Director Strategic Advisor and Special Assistant to CEO, BeiGene
Michael joined BeiGene in 2017 and serves as Strategic Advisor and Special Assistant to the CEO. In addition, Michael oversees Global IT, Global Workplace Services, and U.S. Government Affairs. Prior to that he was Chief of Staff and Special Advisor to the CEO as well as SVP, Business Operations, overseeing Global HR, Global IT, Global Workplace Services, and U.S. Corporate Communications. In all those roles Michael works closely with John V. Oyler and other senior management to help direct BeiGene’s operations and work to meet its goals.
In addition, Michael serves as BeiGene’s representative on the board of Pi Health Inc., an oncology-focused health technology and clinical research company, previously a wholly owned subsidiary of BeiGene spun off in 2024.Before joining BeiGene, Michael was a Managing Director and the Regional Head of Latin America and Caribbean Debt Capital Markets and Derivative Solutions for Scotiabank, based in New York. In this capacity, he was responsible for overseeing the origination and execution of all debt and derivative transactions from and within the region. Michael joined Scotiabank in early 2013 after twelve years in a similar capacity at Credit Suisse. Michael joined Credit Suisse in 2000 when the bank merged with Donaldson, Lufkin & Jenrette, where he was a member of the High Yield Capital Markets group. Prior to that, Michael worked at J.P. Morgan and Lehman Brothers, respectively, in their Emerging Markets groups.
Michael graduated from the Massachusetts Institute of Technology with a Bachelor of Science in Management from the Sloan School of Management. Michael is Chairman of the Board of Directors for HealthCare Chaplaincy Network, Inc., a leader in the research, education, and practice of spirituality within health care and palliative care, as well as . He also serves on the Board of Trustees of BioNJ, the life sciences trade association for New Jersey. Michael grew up in Ohio and has long been a supporter of The Ohio State University’s James Cancer Center through Pelotonia, a cancer fundraising ride. In 2023 he was awarded the Pelotonia Legacy Award, in part for raising over $1.1M over the past fourteen years to support cancer research.
In addition, Michael serves as BeiGene’s representative on the board of Pi Health Inc., an oncology-focused health technology and clinical research company, previously a wholly owned subsidiary of BeiGene spun off in 2024.Before joining BeiGene, Michael was a Managing Director and the Regional Head of Latin America and Caribbean Debt Capital Markets and Derivative Solutions for Scotiabank, based in New York. In this capacity, he was responsible for overseeing the origination and execution of all debt and derivative transactions from and within the region. Michael joined Scotiabank in early 2013 after twelve years in a similar capacity at Credit Suisse. Michael joined Credit Suisse in 2000 when the bank merged with Donaldson, Lufkin & Jenrette, where he was a member of the High Yield Capital Markets group. Prior to that, Michael worked at J.P. Morgan and Lehman Brothers, respectively, in their Emerging Markets groups.
Michael graduated from the Massachusetts Institute of Technology with a Bachelor of Science in Management from the Sloan School of Management. Michael is Chairman of the Board of Directors for HealthCare Chaplaincy Network, Inc., a leader in the research, education, and practice of spirituality within health care and palliative care, as well as . He also serves on the Board of Trustees of BioNJ, the life sciences trade association for New Jersey. Michael grew up in Ohio and has long been a supporter of The Ohio State University’s James Cancer Center through Pelotonia, a cancer fundraising ride. In 2023 he was awarded the Pelotonia Legacy Award, in part for raising over $1.1M over the past fourteen years to support cancer research.
Bobby Reddy, MD
Board Director, CEO of Pi Health
Dr. Bobby Reddy, MD is the Chief Executive Officer of Pi Health. At Pi Health, he leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world. Previously, he served in leadership positions at BeOne Medicines and AstraZeneca. At BeOne, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
